Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated Interferon ALFA-2b in Pediatric Gliomas
NCT02343224Phase 2Completed
- Sponsor
- Emory University
- Start
- Nov 2014
- Primary completion
- Nov 2020
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of peginterferon alfa-2b in Juvenile Pilocytic Astrocytoma (JPA) and optic pathway glioma (OPG), sponsored by Emory University. Primary endpoint: Number of Children Responding to Treatment at 12 months. Started Nov 2014; status: completed.
02
Drugs
peginterferon alfa-2b
03
Conditions
Juvenile Pilocytic Astrocytoma (JPA)optic pathway glioma (OPG)
Beyond the preview
Go deeper on NCT02343224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02343224.